Loading…
Onconetix, Inc. is projected to decline to $0.8234 by 2027, a -15% move from its current price of $0.9669. ONCO is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $0.9001 | $0.9666 | $1.04 | -0.04% |
| Jul 13 | $0.8736 | $0.9662 | $1.07 | -0.07% |
| Jul 14 | $0.8537 | $0.9659 | $1.09 | -0.11% |
| Jul 15 | $0.8373 | $0.9655 | $1.11 | -0.14% |
| Jul 16 | $0.823 | $0.9652 | $1.13 | -0.18% |
| Jul 17 | $0.8103 | $0.9648 | $1.15 | -0.22% |
| Jul 18 | $0.7988 | $0.9645 | $1.16 | -0.25% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.7988 | $0.9645 | $1.16 | -0.25% |
| Week 2 | $0.737 | $0.9621 | $1.26 | -0.50% |
| Week 3 | $0.6924 | $0.9596 | $1.33 | -0.75% |
| Week 4 | $0.6566 | $0.9572 | $1.40 | -1.00% |
| Week 5 | $0.6265 | $0.9548 | $1.46 | -1.25% |
| Week 6 | $0.6003 | $0.9524 | $1.51 | -1.50% |
| Week 7 | $0.577 | $0.9501 | $1.56 | -1.74% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Onconetix, Inc. is a biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology in the United States, the European Union, and Non-European Union. The company offers Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer.
It has license agreements with LabCorp to develop and commercialize Proclarix and other products; and with Immunovia AB for the development, manufacturing, and commercialization of the PancreaSure test. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc.
in December 2023. Onconetix, Inc. was founded in 2018 and is headquartered in Cincinnati, Ohio.
ONCO currently trades at $0.9577 per share, and has a market cap of $3.54M. Its market rank is 5393, reflecting a very small-cap position. The stock’s current price sits near the lower end of its 30-day trading range. This scale of price and market cap places it among smaller biotech names with limited liquidity.
A major floor 20.7% below — a decisive break under it would weaken the trend.
Price is testing support right now (2.8% away) — a key level to hold.
The nearest ceiling, 24.1% above — a clean break opens room to run.
A major ceiling 3628.4% above — clearing it would confirm fresh momentum.
Key ONCO support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ONCO market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.01 | Sell | $0.9861 | Sell |
| MA 10 | $1.02 | Sell | $1.01 | Sell |
| MA 20 | $1.02 | Sell | $1.16 | Sell |
| MA 50 | $2.11 | Sell | $4.77 | Sell |
| MA 100 | $12.11 | Sell | $28.28 | Sell |
| MA 200 | $66.14 | Sell | $867.34 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 32.48 | Neutral |
| Stoch RSI (14) | 75.93 | Neutral |
| CCI (20) | -92.61 | Neutral |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | 0.17 | Buy |
| ROC (12) | -12.15 | Sell |
| Bollinger %B (20,2) | 0.18 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -3.83 | Sell |
| Awesome (5,34) | -0.05 | Sell |
| Ultimate (7,14,28) | 38.60 | Neutral |
| Momentum (10) | -0.04 | Sell |
| Aroon Osc (25) | -28.00 | Sell |
| Hull MA (9) | 0.97 | Buy |
| ADX (14) | 41.99 | Sell |
| ATR (14) | 0.12 | Info |
The 30-day technical picture is NEUTRAL, with RSI14 at 30 indicating room to move before overbought conditions. The stock’s 50-day moving average is $2.38 and the 200-day moving average is $67.64, showing the price is well below longer-term averages. Support is at $0.944 and resistance at $1.26, while the 30-day range spans from $0.5845 to $1.57.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.94 | $0.9669 | $1.29 | 0% | Neutral | |
| $0.5973 | $0.8234 | $1.23 | -15% | Neutral | |
| $0.5626 | $0.8242 | $1.31 | -15% | Neutral | |
| $0.4787 | $0.7387 | $1.23 | -24% | Bearish | |
| $0.4388 | $0.7098 | $1.23 | -27% | Bearish | |
| $0.6793 | $1.15 | $2.06 | +19% | Neutral | |
| $0.6766 | $1.19 | $2.21 | +23% | Bullish | |
| $0.561 | $1.03 | $1.96 | +7% | Neutral | |
| $0.595 | $1.14 | $2.22 | +18% | Neutral | |
| $0.4876 | $0.9682 | $1.93 | 0% | Neutral | |
| $0.7394 | $1.64 | $3.61 | +70% | Bullish | |
| $0.9063 | $2.01 | $4.63 | +108% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $0.94 | $0.9669 | $1.23 | +0.00% |
| August 2026 | $0.8225 | $0.9967 | $1.26 | +3.08% |
| September 2026 | $0.7614 | $0.9358 | $1.21 | -6.11% |
| October 2026 | $0.7613 | $0.9471 | $1.24 | +1.21% |
| November 2026 | $0.7848 | $0.9864 | $1.31 | +4.15% |
| December 2026 | $0.7517 | $0.954 | $1.29 | -3.29% |
Click any year to see its month-by-month ONCO forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, ONCO is projected to trade between $0.94 and $1.29, averaging $0.9669 — a potential gain of 0% from today's $0.9669. Price action looks broadly range-bound.
Onconetix, Inc.'s 2027 outlook centres on $0.8234, within a $0.5973 to $1.23 range. That is -15% versus the projected 2026 average. That marks a -15% change versus current levels. A consolidation phase looks the most probable path here.
By 2028, ONCO could reach as high as $1.31, with a base case around $0.8242 and support toward $0.5626 — roughly -15% from $0.9669. Price action looks broadly range-bound.
Expect ONCO to range from $0.4787 to $1.23 through 2029. The $0.7387 average target implies a -24% move from current prices. That is -10% versus the projected 2028 average. Expect choppier, lower action through this leg of the cycle.
The ONCO price prediction for 2030 points to an average of $0.7098 (low $0.4388, high $1.23) — a potential decline of -27% on today's $0.9669. A cyclical pullback looks likely — prices rarely move in a straight line.
In 2031, ONCO is projected to trade between $0.6793 and $2.06, averaging $1.15 — a potential gain of +19% from today's $0.9669. That is up +62% on the projected 2030 average. A consolidation phase looks the most probable path here.
Onconetix, Inc.'s 2032 outlook centres on $1.19, within a $0.6766 to $2.21 range. That is up +4% on the projected 2031 average. That marks a +23% change versus current levels. Momentum favours further upside here.
By 2033, ONCO could reach as high as $1.96, with a base case around $1.03 and support toward $0.561 — roughly +7% from $0.9669. A consolidation phase looks the most probable path here.
Expect ONCO to range from $0.595 to $2.22 through 2034. The $1.14 average target implies a +18% move from current prices. That is up +10% on the projected 2033 average. Price action looks broadly range-bound.
The ONCO price prediction for 2035 points to an average of $0.9682 (low $0.4876, high $1.93) — a potential gain of 0% on today's $0.9669. A consolidation phase looks the most probable path here.
In 2040, ONCO is projected to trade between $0.7394 and $3.61, averaging $1.64 — a potential gain of +70% from today's $0.9669. That is up +70% on the projected 2035 average. Momentum favours further upside here.
Onconetix, Inc.'s 2050 outlook centres on $2.01, within a $0.9063 to $4.63 range. That is up +23% on the projected 2040 average. That marks a +108% change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in ONCO today (≈ 1,034.233116 ONCO) could be worth
$2,082.94
+$1,082.94 (+108%) by 2050 · US Dollar
Based on the average projected ONCO price of $2.01 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ONCOwould be worth at today's price.
$1,000 invested in ONCO on Jul 10, 2025 (≈ 4.576659 ONCO) would be worth
$4.43
-$995.57 (-99.6%) today · 0.00× · US Dollar
Based on a ONCO entry price of $218.5 vs. today's $0.9669.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.956 | $1,011.4 | +1.1% |
| 1 month ago | $1.05 | $920.86 | -7.9% |
| 3 months ago | $10.9 | $88.71 | -91.1% |
| 6 months ago | $80 | $12.09 | -98.8% |
| 1 year ago | $218.5 | $4.43 | -99.6% |
| All time (4.4y) ago | $9,758,000 | $0 | -100.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ONCO forecast.
Our base-case forecast reaches $1.90 around 2050.
Implied market cap at $1.90: $7.01M
The year-by-year forecast depicts a varied multi-year path. For 2026 the min is $0.944, the avg is $0.9577, the max is $1.27, with a 0% ROI and NEUTRAL sentiment. 2027 and 2028 remain NEUTRAL with negative ROI (-14.5% and -14.9% respectively).
2029 shows a Bearish tilt with min $0.4712, avg $0.7272, max $1.21 and -24.1% ROI. 2030 remains Bearish with min $0.4377, avg $0.7082, max $1.23 and -26.1% ROI. 2031 turns Neutral to 1.14 on avg with 19.1% ROI, and 2032 improves to 1.18 on avg with 22.9% ROI.
2033–2035 stay in Neutral territory with modest gains and occasional dips (avg $1.02, $1.13, $0.9558; ROIs 6.7%, 17.8%, -0.2%). The path brightens into 2040, with avg $1.63, max $3.57 and 70% ROI in a Bullish year, followed by 2050 with avg $1.99, max $4.57 and 107.7% ROI in a further Bullish outcome. These are estimates, not guarantees, and reflect a wide dispersion of possible outcomes across the horizon.
Tap a question to reveal the answer.
The 2030 forecast shows min $0.4377, avg $0.7082, max $1.23 with a -26.1% ROI and a Bearish sentiment.
Forecasts indicate a mixed path with several Bearish years early on and Bullish turns later, including a 2050 forecast of avg $1.99 with 107.7% ROI. These are estimates and not guarantees, and risks are inherent.
Yes. The forecast max prices exceed $2 in multiple years: 2031 max $2.05, 2032 max $2.18, and higher in later years (2040 max $3.57 and 2050 max $4.57).
The current 30-day high is $1.57. Forecasts show higher peaks in later years (e.g., 2040 max $3.57 and 2050 max $4.57), while the 2026 max is $1.27.
The current price is $0.9577 and the market cap is $3.54M.
Onconetix, Inc. Community Discussion
0Share your Onconetix, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.